Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Trial Profile

Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors BIAL - Portela C S.A.
  • Most Recent Events

    • 27 Apr 2018 Results of a pooled analysis from NCT00988156 and NCT01527513 studies, presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 27 Apr 2018 Results of post hoc analysis of data pooled from NCT01527513 and NCT00988156 trials evaluating safety and tolerability presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results of post hoc analysis of data pooled from NCT01527513 and NCT00988156 trials evaluating safety and efficacy presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top